Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06322641 · ClinicalTrials.gov registry record
A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 300
- Enrollment target
NCT06322641 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 300 participants.
The verdict
NCT06322641 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD)
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2024-05-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06322641
The ClinicalTrials.gov registry entry for NCT06322641 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT06322641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06322641 about?
NCT06322641 is a clinical study titled "A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists". The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD)
What is the current status of trial NCT06322641?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2024-03-26. Estimated completion is 2024-05-10.
What interventions are being tested in trial NCT06322641?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT06322641?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.